← brief for 2026-09-10 · Slowing decline

SGLT2 Inhibitors in Nephrolithiasis: Emerging Evidence and What Urologists Need to Know

Paper C Peer reviewed Observational

Key takeaways

This review pulls together what is known about SGLT2 inhibitors and kidney stones. SGLT2 inhibitors are diabetes drugs that also slow kidney decline. The evidence so far comes from watching patients rather than testing the drugs against stones directly, so it shows a link, not proof that these drugs prevent stones.

Who did this work

Marius Ivănuță (Grigore T. Popa University of Medicine and Pharmacy) · Dragoş Puia (Grigore T. Popa University of Medicine and Pharmacy) · Ana-Maria Ivănuță (Spitalul Clinic Judeţean de Urgenţe "Sf. Spiridon" Iaşi) · Alexandra Haută (Grigore T. Popa University of Medicine and Pharmacy) · Ionuț Nistor (Grigore T. Popa University of Medicine and Pharmacy) · Cătălin Pricop (Grigore T. Popa University of Medicine and Pharmacy)

Source

Paper · OpenAlex, CKD works · 2026-09-09
https://doi.org/10.3390/medsci14050555